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Abstract A common mutation in P53 protein occurs at amino
acid residue 281 in the DNA binding domain (P53gly281), which
results in loss of transcriptional regulation of P53 target genes
and has been reported to gain pro-oncogenic functions. In the
present study, we investigated the activity of P53gly281 in P53-
null PC3 human prostate cancer cells and found that the
P53gly281 induced apoptosis as efficiently as the wild-type P53
(wtP53). However, in contrast to wtP53-induced apoptosis, the
P53gly281-induced apoptosis was insensitive to overexpression of
bcl-2. Thus, our findings indicate that while a mutation in the
DNA binding domain of p53 may result in a more oncogenic form
of the protein, it may also paradoxically result in the ‘gain’ of a
new, alternative pathway for apoptosis. ß 2002 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
P53 is a well-characterized tumor suppressor gene and p53
mutations are closely associated with most advanced malig-
nant tumors [1,2]. Functions of P53 protein include growth
arrest, di¡erentiation and apoptosis, depending on the cellular
context [3^9]. It is generally accepted that P53 induces cell
arrest by increasing P21 at the transcriptional level [10,11].
However, the mechanism of P53-induced apoptosis may be
more complicated. P53 can induce apoptosis by increasing
the expression of Fas or bax genes through binding to the
P53-speci¢c binding sequence in the regulatory region of these
genes [12]. However, some early work showed that P53-in-
duced apoptosis may not necessarily be dependent on tran-
scriptional activity since P53-dependent apoptosis could occur
in the presence of inhibitors of transcription or translation
[13,14]. Recently, it was reported that the transcription-de¢-
cient P53 with mutations at the 22^23 amino acid residues [15]
are still capable of inducing apoptosis [16,17]. In contrast,
others have shown that the same p53 mutant was unable to
induce apoptosis [18^20]. Most recently, the results from stud-
ies of murine p53 gene mutations also supported the observa-
tion that transcriptional activity is required for P53-induced
apoptosis [21,22].
The transactivation domain of P53 protein requires 42 ami-
no acids at the amino terminus, especially residues 22 and 23,
which interact with the basal transcriptional elements of target
genes to regulate transcriptional machinery of the cell [15,23^
28]. The sequence-speci¢c DNA binding domain (the core
DNA binding domain) is located in the middle of the protein
between amino acids 102 and 292 and binds to the regulatory
region of its target genes [29^32]. More recent studies have
demonstrated that the C-terminus is involved in regulating
both the DNA binding and apoptosis activities of P53 [33,34].
It is believed that P53 protein with mutations at certain
‘hot-spots’ such as amino acid residue 248 (ArgCTrp) or
281 (AspCGly) fail to bind to the P53-speci¢c binding region
of the target gene and lose the original transactivation func-
tion [12]. Interestingly, the P53gly281 mutant has been known
to have a gain of function phenomenon in a few P53-null cell
lines. In particular, this mutant transcriptionally upregulates
expression of certain genes such as multidrug resistant gene
type-1 [35] and HIV long terminal repeat [36]. It also enhances
the tumorigenic potential of some cells [35]. Thus, it is gen-
erally believed that this mutant P53 protein not only antago-
nizes wild type p53 (wtP53) to interfere with its normal func-
tions, it is also more oncogenetic due to a gain of abnormal
functions [37^39]. In the present study, we investigated this
mutant in another P53-null cell line, the prostate cancer PC3
cells, and found that the P53gly281 mutant possesses a gain of
apoptotic pathway distinct from that of wtp53.
2. Materials and methods
2.1. Cell culture
The human prostate cancer PC3 cell line was obtained from Amer-
ican Type Culture Collection (Rockville, MD, USA). The cell line was
maintained in RPMI 1640 medium (Gibco BRL, Burlington, ON,
Canada) supplemented with 5% fetal bovine serum containing anti-
biotic mixture at 37‡C under a humidi¢ed 5% CO2 atmosphere.
2.2. DNA and transfection
Plasmids containing wtp53 or mutant p53 cDNA were kindly pro-
vided by Dr. Levine (Department of Molecular Biology, Princeton
University). The plasmid p53gly281 consists of mutant p53 cDNA at
residue 281, changing aspartic acid to glycine, which is in the se-
quence-speci¢c DNA binding domain. PC3 cells (5U105) were seeded
in 60 mm culture dishes the day before transfection. Cells were trans-
fected with a total of 3.5 Wg DNA plasmids puri¢ed with Qiagen
maxi-preparation kit (Mississauga, ON, Canada)
2.3. Hypodiploid DNA apoptosis analysis
Samples containing 106 of cells/60 mm dish were harvested follow-
ing brief trypsin digestion (Gibco BRL, Burlington, ON, Canada).
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The cells were ¢xed with 70% ice-cold ethanol on ice for 30 min
followed by treatment with RNaseA (1 mg/ml) and propidium iodide
(PI) (50 Wg/ml). DNA analyses were determined using an Flow cy-
tometer (Epics Elite ESP, Beckman Coulter) and a DNA content log-
histogram was generated. [40,41].
2.4. Determination of Fas and FasL expression by £ow cytometric
analysis
The total amount of expression of Fas antigen in PC3 cells in total
and that on the cell surface were determined by £ow cytometry. For
cell surface staining, the cells (2U105) were pretreated with human
IgG (ICN Immunobiologicals, Lisele, IL, USA, 50 Wg/ml) for 10 min
on ice, and then incubated 30 min on ice with R-Phycoerythrin
(R-PE)-conjugated mouse anti-human Fas monoclonal antibody or
R-PE-labeled mouse IgG1 monoclonal isotype control (Pharmingen,
Canada), then washed twice and resuspended in PBS containing 1 Wg/
ml of PI (Sigma Chemical Co., St. Louis, MO, USA). For total
staining, 2U105 cells were ¢xed in 2% paraformaldehyde for 15 min
at room temperature and then incubated in 10% Tween-20 for another
15 min to permeabilize the cells. The staining procedure was the same
as for surface staining, except £uorescein isothiocyanate (FITC)-con-
jugated mouse anti-human monoclonal antibody and FITC-labeled
mouse IgG1 monoclonal isotype control (Pharmingen Canada) were
used.
3. Results
3.1. p53gly281 mutant can activate apoptosis in PC3 cells
3.1.1. P53-induced apoptosis. Expression of the P53 pro-
teins was con¢rmed in transfected cells by Western blotting
using a P53-speci¢c monoclonal antibody that recognized
both wild type and mutant P53 (data not shown). Flow cyto-
metry results demonstrated a typical hypodiploid peak as an
indication of apoptosis in cells transfected with either wtp53
or p53gly281, respectively (Fig. 1). Nearly one third of the cells
(30.8% þ 6.1, n = 6) were apoptotic 48 h after wtp53 transfec-
tion relative to the untreated control samples. Interestingly,
transfection with p53gly281 cDNA also resulted in apoptosis
(22.1% þ 3.0, n = 6), which was at a level similar to that in-
duced by wtp53 (P = 0.124, Student’s t-test). To rule out the
variation caused by di¡erence in transfection e⁄ciency among
cell cultures, a construct carrying the gene of green £uorescent
protein (GFP) was co-transfected with the above p53 gene
constructs. No signi¢cant di¡erence in GFP expression was
found with £ow cytometry across all the cell cultures exam-
ined.
To con¢rm the apoptotic nature of the cell death, nuclear
fragmentation was seen in cells stained with Hoechst 33342
under a £uorescent microscope 24^48 h after transfection
(data not shown).
3.2. The P53gly281 mutant was not able to transcriptionally
upregulate Fas and BAX synthesis
To verify that the apoptotic activity seen in P53gly281 was
not through the same mechanism as wtP53 in PC3 cells, we
¢rst tested the ability of this mutant P53 to upregulate Fas or
BAX expression in PC3 cells, since the two genes are the well-
known targets that are transcriptionally regulated by wtP53.
3.2.1. Fas expression in p53-transfected cells. Transient ex-
pression of P53 into PC3 cells caused increased levels of Fas
as measured by £ow cytometry (Fig. 2a). To minimize varia-
tion caused by transfection e⁄ciency, we co-transfected a
Fig. 1. Representative £ow cytometry results for PC3 cells showing apoptotic e¡ect following transfection with wtp53 or mutant p53. The sub-
population of apoptotic cells was represented by the area for cells with sub-diploid DNA content. The marker on the top of each plot repre-
sents the cut-o¡ point for calculating percentage of this cell population. A: Untransfected; B: vector control; C: wtp53; D: P53gly281.
Fig. 2. a: E¡ects of P53 on Fas expression in PC3 cells. Cells were transfected with either wtp53 or p53gly281 mutant constructs and the Fas
expression levels were measured with £ow cytometry. The base line expression level was determined with cell cultures transfected with control
plasmid pGL2 and the results shown are the mean di¡erences ( þ S.E.M.) between the p53-transfected cells and control from two experiments.
b: E¡ects of P53 on levels of Bax in PC3 cells. Cells were transfected with control vector or wtp53 or p53gly281 mutant constructs and the Bax
expression levels were measured with Western blotting. A: control; B: p53gly281 transfected; and C: wtp53 transfected.
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GFP-expressing plasmid with the wtp53 or p53gly281. Only
GFP-positive cells were gated for the measurement of Fas
levels on the cell surface. As shown in Fig. 2a, after trans-
fection of the wtp53 gene, Fas expression was increased both
in total and on the cell surface by 33 þ 7.1% and 30 þ 8.0%,
respectively (n = 4, P6 0.005). Since the amount of increased
Fas expression on the cell surface was similar to that in the
total (Fig. 2a), the increased Fas antigen on the cell surface
following the expression of wtP53 was likely due to increased
newly synthesized Fas rather than redistribution due to a
translocation mechanism. Thus, the increased Fas level on
the cell surface was mainly caused by enhanced transcriptional
activity of fas gene regulated by the transfected p53. In con-
trast, transfection with the p53gly281 had no e¡ect on the Fas
expression in PC3 cells (n = 4, Ps 0.05) (Fig. 2a).
Results of P53-induced Bax expression were shown in Fig.
2b. While the level of Bax was substantially upregulated by
transfected wtp53 at 24 h, Bax level in cells transfected with
p53gly281 remained low.
In separate experiments (data not shown), we also found
that in PC3 cells, transfection with P53gly281 could not induce
p21 gene expression nor G1 arrest, which are other hallmark
measures for the normal function of P53 [44]. It is thus ap-
parent that the mutation in the DNA binding domain in
P53gly281 disabled P53 function of transcriptional regulation
in these cells.
3.3. Bcl-2 can inhibit wtP53 but not P53gly281 activation of
apoptosis
As Fas ligand was not required in wtP53-induced apoptosis
of PC3 cells, it was apparent that the Fas pathway was not
involved. Another possible P53-induced apoptotic pathway is
through activating Bax [42,43]. Since Bcl-2 can form hetero-
dimers with Bax, overexpression of Bcl-2 can block apoptosis
induced by Bax. We examined the e¡ect of Bcl-2 by co-trans-
fecting a bcl-2 cDNA with the above p53 genes. As shown in
Fig. 3, co-transfection with Bcl-2 signi¢cantly reduced the ap-
optosis induced by wtP53 (P6 0.05, t-test). This suggested
that the P53-induced apoptosis in PC3 cells was mediated
primarily through the Bax/Bcl-2 pathway. In contrast, over-
expression of Bcl-2 had no signi¢cant e¡ect on the apoptosis
induced by the p53gly281 (Ps 0.05). In addition, transfection
with p53gly281 did not induce upregulation of Bax levels in
PC3 cells examined by Western blotting (Fig. 2b). This indi-
cated that the mutant non-transcriptionally active form of P53
had acquired a mechanism distinct from that of wtP53 to elicit
an apoptotic response.
4. Discussion
In the present study, we demonstrated that, despite the lack
of P53-speci¢c transactivation function, the P53gly281 mutant
was able to induce apoptosis to an extent similar to that seen
with wtP53 (Fig. 1). To distinguish the mechanism for the
mutant P53-induced apoptosis from that of wtP53, we ¢rst
con¢rmed that the P53gly281 had lost P53-speci¢c transacti-
vation activity in PC3 cells by demonstrating that P53gly281
failed to induce Fas expression, which is a known transcrip-
tionally regulated target gene of wtP53. Although overexpres-
sion of Bcl-2 blocked wtP53-induced apoptosis to near control
levels, it had no e¡ect on the activity of the P53gly281 mutant.
The reported e¡ects of gain of function for P53gly281 in
transfected cells have been to cause the cells to become either
more oncogenic or more resistant to apoptosis [37^39]. This is
the ¢rst time to our knowledge that an apoptotic function of
the p53gly281 has been demonstrated. Based on the observa-
tions that P53gly281 has lost the ability to bind to a P53-
speci¢c DNA binding sequence [45] and that the P53gly281-
induced apoptosis was insensitive to Bcl-2, we speculate that
P53gly281 may activate another apoptotic pathway distinct
from the mechanisms of wtP53. Thus, the phenomenon of
P53gly281-induced apoptosis is essentially a ‘gain of pathway’,
which may act through binding directly to the regulatory re-
gion of a new target gene or by interacting with a new target
protein. Recently, it has been suggested that the C-terminal
basic domain and parts of the N-terminal, including the pro-
line-rich domain, are required for apoptotic activity of P53
[33,34,46]. It will be interesting to investigate the roles of these
regions in P53gly281 in the induction of apoptosis in PC3 cells.
The results reported in the present study indicate the complex-
ity of P53 mutations, where a mutant can be anti-apoptotic in
some cancer cells while pro-apoptotic in others.
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